|
US5034506A
(en)
|
1985-03-15 |
1991-07-23 |
Anti-Gene Development Group |
Uncharged morpholino-based polymers having achiral intersubunit linkages
|
|
US6699475B1
(en)
|
1987-09-02 |
2004-03-02 |
Therion Biologics Corporation |
Recombinant pox virus for immunization against tumor-associated antigens
|
|
KR920003787B1
(ko)
|
1990-03-05 |
1992-05-14 |
한국과학기술 연구원 |
신규 플라스미드 제조 및 그를 함유한 균주를 배양하여 아이 지 에프-1(igf-1)을 생산하는 방법
|
|
US5571711A
(en)
|
1993-06-17 |
1996-11-05 |
Ludwig Institute For Cancer Research |
Isolated nucleic acid molecules coding for BAGE tumor rejection antigen precursors
|
|
US5821122A
(en)
|
1995-06-07 |
1998-10-13 |
Inserm (Institute Nat'l De La Sante Et De La Recherche . .) |
Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
|
|
CA2341897A1
(en)
|
1998-08-28 |
2000-03-09 |
Uropath Pty. Ltd. |
Method of diagnosis of prostate cancer
|
|
CA2369433A1
(en)
|
1999-02-26 |
2000-08-31 |
Pacific Northwest Research Institute |
Methods and compositions for diagnosing carcinomas
|
|
US6673545B2
(en)
|
2000-07-28 |
2004-01-06 |
Incyte Corporation |
Prostate cancer markers
|
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
|
AU2003281200A1
(en)
|
2002-07-03 |
2004-01-23 |
Tasuku Honjo |
Immunopotentiating compositions
|
|
CN101899114A
(zh)
|
2002-12-23 |
2010-12-01 |
惠氏公司 |
抗pd-1抗体及其用途
|
|
US7563869B2
(en)
|
2003-01-23 |
2009-07-21 |
Ono Pharmaceutical Co., Ltd. |
Substance specific to human PD-1
|
|
DK2439273T3
(da)
|
2005-05-09 |
2019-06-03 |
Ono Pharmaceutical Co |
Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
|
|
CA2611861C
(en)
|
2005-06-08 |
2017-11-28 |
The Brigham And Women's Hospital, Inc. |
Methods and compositions for the treatment of persistent infections
|
|
PT1907424E
(pt)
|
2005-07-01 |
2015-10-09 |
Squibb & Sons Llc |
Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
|
|
US20070258889A1
(en)
|
2005-11-09 |
2007-11-08 |
Montana State University |
Novel nanoparticles and use thereof
|
|
US8575359B2
(en)
|
2006-04-04 |
2013-11-05 |
The Regents Of The University Of California |
Acid-sensitive linkers for drug delivery
|
|
KR101523391B1
(ko)
|
2006-12-27 |
2015-05-27 |
에모리 유니버시티 |
감염 및 종양 치료를 위한 조성물 및 방법
|
|
WO2009014708A2
(en)
|
2007-07-23 |
2009-01-29 |
Cell Genesys, Inc. |
Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
|
|
CL2008003526A1
(es)
|
2007-11-30 |
2010-01-11 |
Medarex Inc |
Conjugado de anticuerpo-molécula asociada que comprende un anticuerpo monoclonal humano anti b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8 humana; composición que lo comprende; método in vitro de inhibición de célula tumoral que expresa b7-h4/08e/b7x/b7s1/bl-cam/b3/leu-14/lyb-8; y uso para tratar cancer.
|
|
JPWO2010029947A1
(ja)
*
|
2008-09-09 |
2012-02-02 |
国立大学法人京都大学 |
造影剤組成物及びその製造方法
|
|
BR112013021732B1
(pt)
*
|
2011-02-25 |
2021-11-30 |
South Dakota State University |
Micela estável e utilização da micela estável
|
|
BR112014014262A2
(pt)
*
|
2011-12-14 |
2017-06-13 |
Univ Johns Hopkins |
nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
|
|
WO2014031727A1
(en)
|
2012-08-21 |
2014-02-27 |
Brown University |
Ferritin-based tumor targeting agent, and imaging and treatment methods
|
|
EP3197920B1
(en)
*
|
2014-09-25 |
2021-01-13 |
Nanyang Technological University |
Targeting of melanocytes for delivering therapeutic or diagnostic agents using protein nanocages
|